C4 Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M | $78.4M | $48.1M |
| SG&A Expense | — | $36.2M | $42.1M | $42.1M | $42.8M | $33.3M | $15.2M | $8.8M |
| Operating Income | — | $-115.2M | $-119.6M | $-139.0M | $-129.5M | $-82.1M | $-60.4M | $-35.5M |
| Operating Margin | — | -320.5% | -336.1% | -669.8% | -416.6% | -179.4% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-104.9M | $-105.2M | $-131.2M | $-128.2M | $-83.9M | $-67.0M | $-33.3M |
| Income Tax Expense | — | $121.0K | $131.0K | $1.3M | $0 | $0 | $-626.0K | $804.0K |
| Net Income | — | $-105.0M | $-105.3M | $-132.5M | $-128.2M | $-83.9M | $-66.3M | $-34.1M |
| Net Margin | — | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% | — | — |
| EPS (Basic) | — | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-5.83 | $-31.03 |
| EPS (Diluted) | — | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-5.83 | $-31.03 |
| Shares Outstanding (Basic) | 97.6M | 82.9M | 69.4M | 49.6M | 48.9M | 46.0M | 43.1M | 1.4M |
| Shares Outstanding (Diluted) | 97.6M | 82.9M | 69.4M | 49.6M | 48.9M | 46.0M | 43.1M | 1.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |